ESPR Stock Price, Esperion Therapeutics Quote, Chart

Market Summary

USD2.03-0.34

Market Closed

-14.35%

ESPR Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

ESPR Stock Price

View Fullscreen

ESPR RSI Chart

ESPR Valuation

Market Cap

384.6M

Price/Earnings (Trailing)

-4.45

Price/Sales (Trailing)

1.67

Price/Free Cashflow

-16.45

ESPR Price/Sales (Trailing)

ESPR Profitability

Return on Equity

29.39%

Return on Assets

-23.19%

Free Cashflow Yield

-6.08%

ESPR Fundamentals

ESPR Revenue

Revenue (TTM)

229.7M

Rev. Growth (Yr)

466.14%

Rev. Growth (Qtr)

327.09%

ESPR Earnings

Earnings (TTM)

-86.5M

Earnings Growth (Yr)

198.87%

Earnings Growth (Qtr)

208.3%

Breaking Down ESPR Revenue

Last 7 days

-0.5%

Last 30 days

-33%

Last 90 days

-21.3%

Trailing 12 Months

43.0%

How does ESPR drawdown profile look like?

ESPR Financial Health

Current Ratio

2.22

Debt/Equity

5e-4

Debt/Cashflow

-195.02

ESPR Investor Care

Shares Dilution (1Y)

100.04%

Diluted EPS (TTM)

-0.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	229.7M	0	0	0
2023	81.0M	87.9M	102.9M	116.3M
2022	89.3M	67.5M	72.1M	75.5M
2021	233.7M	62.1M	72.7M	78.4M
2020	168.2M	188.0M	207.8M	227.5M
2019	0	0	0	148.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Esperion Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	warren eric	acquired	-	-	100,000	chief commercial officer
Mar 14, 2024	foody joanne m.	acquired	-	-	150,000	chief medical officer
Mar 14, 2024	halladay benjamin	acquired	-	-	170,000	chief financial officer
Mar 14, 2024	koenig sheldon l.	acquired	-	-	454,000	president and ceo
Mar 14, 2024	looker benjamin	acquired	-	-	100,000	general counsel
Sep 20, 2023	warren eric	sold	-923	1.245	-742	chief commercial officer
Aug 18, 2023	warren eric	sold	-343	1.414	-243	chief commercial officer
Jul 19, 2023	warren eric	sold	-168	1.585	-106	chief commercial officer
Jun 21, 2023	warren eric	sold	-894	1.483	-603	chief commercial officer
Jun 15, 2023	fischer seth h. z.	acquired	-	-	5,150	-

Which funds bought or sold ESPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Susquehanna Portfolio Strategies, LLC	reduced	-20.6	-100,212	247,364	0.01%
May 07, 2024	ASSETMARK, INC	new	-	21.00	21.00	-%
May 07, 2024	O'Dell Group, LLC	sold off	-100	-13,455	-	-%
May 07, 2024	CVI Holdings, LLC	new	-	36,807	36,807	0.04%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	47.15	1,325,740	5,482,660	-%
May 07, 2024	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	new	-	446,105	446,105	0.02%
May 07, 2024	Cornerstone Planning Group LLC	unchanged	-	-112	256	-%
May 07, 2024	Headlands Technologies LLC	sold off	-100	-9,592	-	-%
May 06, 2024	HighTower Advisors, LLC	added	277	347,000	496,000	-%
May 06, 2024	STONERIDGE INVESTMENT PARTNERS LLC	added	219	163,000	250,000	0.10%

Are Funds Buying or Selling ESPR?

Are funds buying ESPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ESPR

No. of Funds

Unveiling Esperion Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	two seas capital lp	6.8%	7,686,120	SC 13G/A
Feb 14, 2024	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2024	cvi investments, inc.	0%	0	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	0.1%	4,800	SC 13G/A
Feb 13, 2024	vanguard group inc	4.52%	5,137,750	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Jan 24, 2024	bb biotech ag	5.1%	9,194,064	SC 13G/A
Jan 24, 2024	bb biotech ag	3.7%	4,194,064	SC 13G/A
Jan 17, 2024	millennium management llc	3.2%	3,643,951	SC 13G/A
Jan 03, 2024	meditor group ltd	3.3%	3,791,300	SC 13G/A

Recent SEC filings of Esperion Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading

Peers (Alternatives to Esperion Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	358.5B	85.6B	-1.74%	-7.51%	9.32	4.19	5.68%	202.39%
MRK	328.0B	61.4B	2.34%	10.30%	142.26	5.34	6.11%	-82.30%
AMGN	164.9B	29.5B	14.19%	31.13%	43.82	5.58	12.76%	-52.47%
PFE	159.7B	46.5B	6.40%	-25.71%	-115.01	3.43	42.59%	-114.62%
GILD	80.9B	27.1B	-6.51%	-17.64%	14.27	2.98	-0.60%	23.36%
TEVA	17.6B	15.8B	10.77%	72.86%	-30.59	1.11	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.6B	-2.02%	-10.81%	-550.77	0.93	-0.06%	94.55%
ALKS	4.1B	1.7B	-7.02%	-22.02%	9.39	2.36	54.01%	364.56%
BHC	2.6B	9.0B	-27.55%	19.80%	-5.66	0.29	10.01%	-27.45%
AMPH	2.0B	644.4M	2.87%	15.89%	14.77	3.15	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-25.10%	-28.68%	-4.27	2.02	24.65%	80.36%
TXMD	23.3M	1.3M	-6.48%	-47.40%	-2.27	17.89	-98.14%	-109.18%
ACRX	17.5M	-	-11.21%	50.12%	-0.95	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	5.13%	-93.31%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Esperion Therapeutics Inc News

Latest updates

Esperion Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	327.1%	138	32.00	34.00	26.00	24.00	19.00	19.00	19.00	19.00	15.00	14.00	41.00	8.00	10.00	4.00	212	107	1.00	1.00	1.00	145
Operating Expenses	-12.3%	65.00	75.00	62.00	63.00	73.00	61.00	61.00	71.00	62.00	71.00	70.00	73.00	91.00	105	84.00	83.00	76.00	60.00	67.00	56.00	58.00
S&GA Expenses	-7.6%	42.00	45.00	33.00	34.00	30.00	24.00	25.00	30.00	30.00	38.00	39.00	46.00	61.00	62.00	49.00	48.00	42.00	22.00	18.00	13.00	12.00
Interest Expenses	-6.9%	14.00	15.00	15.00	15.00	14.00	14.00	14.00	14.00	14.00	13.00	14.00	11.00	8.00	9.00	5.00	5.00	4.00	4.00	4.00	-	-
Net Income	208.3%	61.00	-56.34	-41.25	-49.93	-61.72	-55.49	-55.12	-66.32	-56.73	-65.12	-69.39	-43.67	-90.93	-104	-85.44	125	-78.25	-61.95	-68.38	-54.22	87.00
Net Income Margin	79.1%	-0.38*	-1.80*	-2.03*	-2.53*	-2.95*	-3.10*	-3.38*	-3.82*	-2.63*	-3.43*	-4.24*	-5.23*	-	-	-	-	-	-	-	-	-
Free Cashflow	245.1%	54.00	-37.06	-19.32	-24.75	-54.36	-42.47	-42.83	-50.53	-38.99	-57.71	-69.17	-47.87	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	81.3%	373	206	221	235	252	248	313	304	343	382	225	280	279	353	251	330	180	214	255	309	236
Current Assets	81.8%	366	201	218	232	251	247	262	252	291	329	171	275	273	346	243	321	173	212	253	307	235
Cash Equivalents	175.5%	227	82.00	115	138	145	125	159	123	150	259	104	219	218	305	216	298	149	167	212	274	175
Inventory	11.4%	73.00	66.00	51.00	46.00	39.00	35.00	30.00	29.00	36.00	34.00	34.00	24.00	20.00	16.00	9.00	8.00	2.00	-	-	-	-
Net PPE	-	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	0.00
Liabilities	1.0%	667	661	631	607	581	572	607	596	592	579	588	585	548	449	242	245	230	194	187	179	61.00
Current Liabilities	5.3%	165	156	138	107	95.00	92.00	82.00	82.00	79.00	73.00	78.00	83.00	98.00	94.00	76.00	84.00	73.00	66.00	58.00	54.00	60.00
Shareholder's Equity	35.3%	-294	-454	-	-	-329	-323	-	-	-	-	-	-	-	-	9.00	85.00	-	20.00	69.00	129	175
Retained Earnings	3.9%	-1,488	-1,549	-1,492	-1,451	-1,401	-1,340	-1,284	-1,229	-1,163	-1,106	-1,041	-971	-928	-838	-734	-648	-773	-695	-633	-564	-510
Additional Paid-In Capital	8.7%	1,249	1,149	1,138	1,135	1,127	1,071	1,045	993	969	964	734	723	714	798	743	734	723	715	702	694	686
Shares Outstanding	64.2%	169	103	100	109	78.00	66.00	64.00	62.00	61.00	29.00	26.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	143	-	-	-	422	-	-	-	593	-	-	-	1,410	-	-	-	1,090	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	245.3%	53,828	-37,056	-19,325	-24,750	-54,356	-42,472	-42,833	-50,532	-38,990	-57,706	-69,169	-47,866	-89,068	-68,550	-86,671	139,391	-69,347	-49,994	-58,029	-54,009	91,691
Share Based Compensation	10.8%	3,235	2,920	2,975	3,160	2,903	3,715	3,537	3,527	4,436	4,474	5,497	8,584	5,751	6,673	7,264	7,395	7,053	6,358	6,327	6,563	6,636
Cashflow From Investing	-Infinity%	-73.00	-	-	17,500	25,000	-11,794	33,000	5,000	-18,102	-50,484	-	-	-	-12,676	2,333	5,110	26,589	-2,868	-5,313	26,716	45,696
Cashflow From Financing	1926.5%	90,606	4,471	-4,312	809	49,492	-30,358	46,292	18,108	-1,436	213,410	3,655	49,113	2,045	170,440	1,597	3,674	26,014	7,014	976	126,536	1,669

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ESPR Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total Revenues	$ 137,735	$ 24,329
Operating expenses:
Cost of goods sold	10,075	11,652
Research and development	13,403	31,381
Selling, general and administrative	41,988	29,901
Total operating expenses	65,466	72,934
Income (loss) from operations	72,269	(48,605)
Interest expense	(14,024)	(14,387)
Other income, net	2,777	1,273
Net income (loss)	$ 61,022	$ (61,719)
Net income (loss) per common share - basic (in dollars per share)	$ 0.36	$ (0.79)
Net income (loss) per common share - diluted (in dollars per share)	$ 0.34	$ (0.79)
Weighted-average shares outstanding - basic (in shares)	169,258,564	78,440,266
Weighted-average shares outstanding - diluted (in shares)	189,641,251	78,440,266
Other comprehensive income (loss):
Unrealized gain on investments	$ 0	$ 1
Comprehensive income (loss)	61,022	(61,718)
Product sales, net
Revenues:
Total Revenues	24,756	17,031
Collaboration revenue
Revenues:
Total Revenues	$ 112,979	$ 7,298

ESPR Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 226,609	$ 82,248
Accounts receivable	54,612	48,494
Prepaid clinical development costs	0	193
Inventories, net	73,095	65,623
Other prepaid and current assets	11,290	4,507
Total current assets	365,606	201,065
Noncurrent assets:
Property and equipment, net	268	0
Right of use operating lease assets	7,130	4,675
Intangible assets	56	56
Total assets	373,060	205,796
Current liabilities:
Accounts payable	28,433	31,718
Accrued clinical development costs	3,046	3,441
Accrued variable consideration	34,518	34,284
Other accrued liabilities	23,140	24,998
Revenue interest liability	43,486	34,828
Deferred revenue from collaborations	29,350	25,402
Operating lease liabilities	2,539	1,553
Total current liabilities	164,512	156,224
Noncurrent liabilities:
Convertible notes, net of issuance costs	262,033	261,596
Revenue interest liability	236,397	239,950
Operating lease liabilities	4,416	3,020
Total liabilities	667,358	660,790
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of March 31, 2024 and 480,000,000 shares authorized as of December 31, 2023; 189,849,296 shares issued at March 31, 2024 and 120,204,513 shares issued at December 31, 2023	188	118
Additional paid-in capital	1,248,774	1,149,170
Treasury stock, at cost; 1,994,198 shares at March 31, 2024 and December 31, 2023	(54,998)	(54,998)
Accumulated other comprehensive income (loss)	0	0
Accumulated deficit	(1,488,262)	(1,549,284)
Total stockholders’ deficit	(294,298)	(454,994)
Total liabilities and stockholders’ deficit	$ 373,060	$ 205,796

About Esperion Therapeutics Inc

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

CEO	Mr. Sheldon L. Koenig
WEBSITE	esperion.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	199

Esperion Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Esperion Therapeutics Inc? What does ESPR stand for in stocks?

ESPR is the stock ticker symbol of Esperion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Esperion Therapeutics Inc (ESPR)?

As of Wed May 08 2024, market cap of Esperion Therapeutics Inc is 384.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ESPR stock?

You can check ESPR's fair value in chart for subscribers.

What is the fair value of ESPR stock?

You can check ESPR's fair value in chart for subscribers. The fair value of Esperion Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Esperion Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ESPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Esperion Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ESPR is over valued or under valued. Whether Esperion Therapeutics Inc is cheap or expensive depends on the assumptions which impact Esperion Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ESPR.

What is Esperion Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, ESPR's PE ratio (Price to Earnings) is -4.45 and Price to Sales (PS) ratio is 1.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ESPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Esperion Therapeutics Inc's stock?

In the past 10 years, Esperion Therapeutics Inc has provided -0.174 (multiply by 100 for percentage) rate of return.